Acura Pharmaceuticals PE Ratio 2012-2021 | ACUR
Current and historical p/e ratio for Acura Pharmaceuticals (ACUR) from 2012 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Acura Pharmaceuticals PE ratio as of June 17, 2026 is 0.00.
| Acura Pharmaceuticals PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-06-17 | 0.00 | 0.00 | |
| 2021-12-31 | 0.50 | $-0.02 | 0.00 |
| 2021-09-30 | 0.53 | $-0.03 | 0.00 |
| 2021-06-30 | 0.66 | $-0.05 | 0.00 |
| 2021-03-31 | 0.33 | $-0.03 | 0.00 |
| 2020-12-31 | 0.21 | $-0.04 | 0.00 |
| 2020-09-30 | 0.25 | $0.02 | 12.50 |
| 2020-06-30 | 0.35 | $0.04 | 8.75 |
| 2020-03-31 | 0.28 | $-0.12 | 0.00 |
| 2019-12-31 | 0.23 | $-0.14 | 0.00 |
| 2019-09-30 | 0.30 | $-0.19 | 0.00 |
| 2019-06-30 | 0.14 | $-0.24 | 0.00 |
| 2019-03-31 | 0.18 | $-0.15 | 0.00 |
| 2018-12-31 | 0.11 | $-0.18 | 0.00 |
| 2018-09-30 | 0.19 | $-0.27 | 0.00 |
| 2018-06-30 | 0.36 | $-0.34 | 0.00 |
| 2018-03-31 | 0.51 | $-0.46 | 0.00 |
| 2017-12-31 | 0.40 | $-0.36 | 0.00 |
| 2017-09-30 | 0.45 | $-0.14 | 0.00 |
| 2017-06-30 | 0.56 | $-0.21 | 0.00 |
| 2017-03-31 | 0.60 | $-0.31 | 0.00 |
| 2016-12-31 | 0.77 | $-0.62 | 0.00 |
| 2016-09-30 | 1.60 | $-0.84 | 0.00 |
| 2016-06-30 | 1.85 | $-0.88 | 0.00 |
| 2016-03-31 | 2.83 | $-0.87 | 0.00 |
| 2015-12-31 | 2.50 | $-0.46 | 0.00 |
| 2015-09-30 | 2.35 | $-0.67 | 0.00 |
| 2015-06-30 | 4.94 | $-0.74 | 0.00 |
| 2015-03-31 | 3.95 | $-0.82 | 0.00 |
| 2014-12-31 | 2.25 | $-1.35 | 0.00 |
| 2014-09-30 | 3.92 | $-1.35 | 0.00 |
| 2014-06-30 | 5.45 | $-1.40 | 0.00 |
| 2014-03-31 | 7.30 | $-1.40 | 0.00 |
| 2013-12-31 | 8.35 | $-1.45 | 0.00 |
| 2013-09-30 | 9.50 | $-1.45 | 0.00 |
| 2013-06-30 | 9.40 | $-1.30 | 0.00 |
| 2013-03-31 | 10.65 | $-1.20 | 0.00 |
| 2012-12-31 | 11.10 | $-1.00 | 0.00 |
| 2012-09-30 | 8.70 | $-0.80 | 0.00 |
| 2012-06-30 | 15.70 | $-0.85 | 0.00 |
| 2012-03-31 | 17.30 | $1.15 | 15.04 |
| 2011-12-31 | 17.45 | $1.10 | 15.86 |
| 2011-09-30 | 17.00 | $0.90 | 18.89 |
| 2011-06-30 | 19.35 | $0.90 | 21.50 |
| 2011-03-31 | 15.80 | $-1.20 | 0.00 |
| 2010-12-31 | 16.55 | $-1.35 | 0.00 |
| 2010-09-30 | 12.45 | $-1.50 | 0.00 |
| 2010-06-30 | 12.55 | $-1.70 | 0.00 |
| 2010-03-31 | 26.95 | $-2.05 | 0.00 |
| 2009-12-31 | 26.65 | $-1.75 | 0.00 |
| 2009-09-30 | 25.55 | $-1.55 | 0.00 |
| 2009-06-30 | 29.90 | $-0.80 | 0.00 |
| 2009-03-31 | 32.10 | $0.55 | 58.36 |
| 2008-12-31 | 36.70 | $1.45 | 25.31 |
| 2008-09-30 | 35.15 | $3.05 | 11.52 |
| 2008-06-30 | 39.75 | $2.45 | 16.22 |
| 2008-03-31 | 43.70 | $1.50 | 29.13 |
| 2007-12-31 | 30.50 | $-0.55 | 0.00 |
| 2007-09-30 | 84.00 | $-4.15 | 0.00 |
| 2007-06-30 | 55.25 | $-4.35 | 0.00 |
| 2007-03-31 | 42.50 | $-4.55 | 0.00 |
| 2006-12-31 | 37.00 | $-3.75 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Halsey Drug Company, Inc. is engaged in the manufacture, sale and distribution of generic drugs. A generic drug is the chemical and therapeutic equivalent of a brand-name drug for which patent protection has expired. The company sells its generic drug products under its Halsey label and under private-label arrangements with drugstore chains and drug wholesalers. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |